On October 1, 2019 Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs), reported the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors (Press release, Avidity Biosciences, OCT 1, 2019, View Source [SID1234539967]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to welcome Sarah as the new CEO of Avidity Biosciences," said Troy Wilson, Ph.D., J.D., Executive Chairman of the Board of Directors, co-founder and founding CEO of Avidity. "Sarah’s broad experience in the healthcare industry, combined with her strategic expertise and track record of leading high-performance teams, position her to be a great partner to both the board and management as we continue to advance our pipeline, optimize our AOC platform and prepare to initiate our first clinical study."
Ms. Boyce brings to Avidity extensive experience in the life sciences industry, where she has built global organizations and brought to patients a number of innovative therapies, including Tegsedi, Waylivra, Soliris, Gleevec and Tasigna. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led commercialization of the company’s rare disease products. Prior to joining Akcea in April 2018, Ms. Boyce held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.
"I am honored by the opportunity the board has extended and am excited to lead Avidity through its next phase of growth," said Sarah Boyce, President and CEO of Avidity Biosciences. "I look forward to working with the leadership team and the board to continue to expand the proprietary AOC technology which combines the benefits of two innovative therapeutic approaches into a pioneering platform and to usher the first wave of potential therapeutics into the clinic."